Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Pharmaceutical giant AbbVie has inked another ...

AbbVie expects full-year earnings in the range of $12.12 to $12.32 per share. AbbVie shares have fallen 1% since the beginning of the year, while the S&P’s 500 index has increased 27%. The stock ...

AbbVie's shares were up 4% at $183.90 as the markets closed Jan. 31. They have gained 11.5% in the last 12 months. Adjusted earnings will be $12.12 to $12.32 a share in 2025, North Chicago ...

AbbVie’s Skyrizi has been approved by the ... induction study called INSPIRE and a 52-week maintenance study called COMMAND. The new use in adults with moderately to severely active UC makes ...

The library eventually took over the entire building before moving to another location in 1991, when the Chicago Cultural Center assumed its current name. The Chicago Cultural Center can be ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking better each quarter for the Illinois drugmaker. On Friday ...

AbbVie will receive royalties on net sales within Greater China. Credit: © AbbVie Inc. All rights reserved. AbbVie and Simcere Zaiming have announced an option-to ...

AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a preclinical-stage, oral drug for psoriasis. US-based Nimble was set up in ...

Shares of AbbVie Inc. (NYSE:ABBV) surged after the company reported strong Q4 2024 results and provided in-line revenue guidance and better-than-expected EPS guidance for 2025. I am very pleased ...